YUMANITY THERAPEUTICS INC (YMTX) Stock Price, Quote, News and Overview
NASDAQ:YMTX - Nasdaq - US98872L1026 - Common Stock - Currency: USD
YMTX Quote, Performance and Key Statistics
1.89
+0.15 (+8.62%)
The current stock price of YMTX is 1.89 USD. In the past month the price increased by 5.59%. In the past year, price decreased by -43.24%.
YMTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About YMTX
Company Profile
Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. The company is headquartered in Boston, Massachusetts and currently employs 40 full-time employees. The company went IPO on 2016-02-11. The firm is focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. The Company’s pipeline consists of programs focused on Parkinson’s disease, Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. The firm's technology platform enables the rapid screening for disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which results from an aberrant accumulation of misfolded proteins in the brain. The firm's product candidate includes YTX-7739, which is in Phase I clinical trials for the treatment and disease modification of Parkinson's disease.
Company Info
YUMANITY THERAPEUTICS INC
40 Guest Street, Suite 4410
Boston MASSACHUSETTS 02135 US
CEO: Richard Peters
Employees: 40
Company Website: https://www.yumanity.com/
Phone: 16174095300.0
YUMANITY THERAPEUTICS INC / YMTX FAQ
What is the stock price of YUMANITY THERAPEUTICS INC today?
The current stock price of YMTX is 1.89 USD. The price increased by 8.62% in the last trading session.
What is the ticker symbol for YUMANITY THERAPEUTICS INC stock?
The exchange symbol of YUMANITY THERAPEUTICS INC is YMTX and it is listed on the Nasdaq exchange.
On which exchange is YMTX stock listed?
YMTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for YUMANITY THERAPEUTICS INC stock?
9 analysts have analysed YMTX and the average price target is 35.7 USD. This implies a price increase of 1788.89% is expected in the next year compared to the current price of 1.89. Check the YUMANITY THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is YUMANITY THERAPEUTICS INC worth?
YUMANITY THERAPEUTICS INC (YMTX) has a market capitalization of 20.52M USD. This makes YMTX a Nano Cap stock.
How many employees does YUMANITY THERAPEUTICS INC have?
YUMANITY THERAPEUTICS INC (YMTX) currently has 40 employees.
What are the support and resistance levels for YUMANITY THERAPEUTICS INC (YMTX) stock?
YUMANITY THERAPEUTICS INC (YMTX) has a support level at 1.68 and a resistance level at 1.98. Check the full technical report for a detailed analysis of YMTX support and resistance levels.
Is YUMANITY THERAPEUTICS INC (YMTX) expected to grow?
The Revenue of YUMANITY THERAPEUTICS INC (YMTX) is expected to grow by 9.96% in the next year. Check the estimates tab for more information on the YMTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy YUMANITY THERAPEUTICS INC (YMTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of YMTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of YMTX, evaluating the profitability, health, valuation and growth aspects
- YUMANITY THERAPEUTICS INC (YMTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- YUMANITY THERAPEUTICS INC (YMTX) Sales and EPS estimates to see what analysts future expectations are.
- YUMANITY THERAPEUTICS INC (YMTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- YUMANITY THERAPEUTICS INC (YMTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- YUMANITY THERAPEUTICS INC (YMTX) Stock Chart to make your own analysis
- YUMANITY THERAPEUTICS INC (YMTX) Latest news and press-releases to stay up to date.
Does YUMANITY THERAPEUTICS INC (YMTX) stock pay dividends?
YMTX does not pay a dividend.
When does YUMANITY THERAPEUTICS INC (YMTX) report earnings?
YUMANITY THERAPEUTICS INC (YMTX) will report earnings on 2023-03-22.
What is the Price/Earnings (PE) ratio of YUMANITY THERAPEUTICS INC (YMTX)?
YUMANITY THERAPEUTICS INC (YMTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.64).
YMTX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to YMTX. When comparing the yearly performance of all stocks, YMTX is a bad performer in the overall market: 64.5% of all stocks are doing better.
YMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to YMTX. YMTX has a bad profitability rating. Also its financial health evaluation is rather negative.
YMTX Financial Highlights
Over the last trailing twelve months YMTX reported a non-GAAP Earnings per Share(EPS) of -2.64. The EPS decreased by -337.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
YMTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to YMTX. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -60.56% and a revenue growth 9.96% for YMTX